Undisclosed antiretroviral drug use in Botswana: Implication for national estimates

Sikhulile Moyo, Simani Gaseitsiwe, Kathleen M. Powis, Molly Pretorius Holme, Terence Mohammed, Melissa Zahralban-Steele, Etienne K. Yankinde, Comfort Maphorisa, William Abrams, Refeletswe Lebelonyane, Kutlo Manyake, Tumalano Sekoto, Mompati Mmalane, Tendani Gaolathe, Kathleen E. Wirth, Joseph Makhema, Shahin Lockman, William Clarke, Max Essex, Vlad Novitsky

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Among 3596 HIV-positive participants enrolled in the Botswana Combination Prevention Project who self-reported no prior antiretroviral (ARV) therapy use and were tested for viral load (n = 951; 27% of all participants), 136 (14%) had HIV-1 RNA less than 400 copies/ml. ARV drugs were detected in 52 (39%) of 134 participants tested. Adjusting for undisclosed ARV use increased the overall estimate of virally suppressed individuals on ARV therapy by 1.4% from 70.2 to 71.6%.

Original languageEnglish (US)
Pages (from-to)1543-1546
Number of pages4
Issue number11
StatePublished - Jul 17 2018

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases


Dive into the research topics of 'Undisclosed antiretroviral drug use in Botswana: Implication for national estimates'. Together they form a unique fingerprint.

Cite this